Source: Eur Respir J, 53 (6) 1801524; 10.1183/13993003.01524-2018
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Kirsty M. Mair, Katie Y. Harvey, Alasdair D. Henry, Dianne Z. Hillyard, Margaret Nilsen, Margaret R. MacLean. Obesity alters oestrogen metabolism and contributes to pulmonary arterial hypertension. Eur Respir J, 53 (6) 1801524; 10.1183/13993003.01524-2018

Member's Comments

No comment yet.

Related content which might interest you: Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects Source: Eur Respir J, 50 (2) 1602337; 10.1183/13993003.02337-2016 Year: 2017 Autoimmunity and pulmonary arterial hypertension: The role of leptin Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Apelin improves cardiac output in patients with pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Evaluation of thyroid function in pulmonary arterial hypertension Source: International Congress 2017 – PAH and CTEPH Year: 2017 Insulin resistance in pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 318-324 Year: 2009 Leptin signalling system as a target for pulmonary arterial hypertension therapy Source: Eur Respir J 2015; 45: 1066-1080 Year: 2015 Interleukin-13-dependent regulation of endothelin-1 expression in pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary hypertension Year: 2007 Inhibiting oestrogen signalling in pulmonary arterial hypertension: sex, drugs and research Source: Eur Respir J, 50 (2) 1700983; 10.1183/13993003.00983-2017 Year: 2017 NMDA receptor crosstalk with PDGFR-β and BMPR2 is involved in smooth muscle cell proliferation in pulmonary arterial hypertension Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Is there an obesity paradox in pulmonary arterial hypertension? Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Impact of therapies on insulin resistance in pulmonary arterial hypertension Source: Annual Congress 2010 - Pulmonary circulation: clinical aspects Year: 2010 Systemic consequences of pulmonary arterial hypertension Source: International Congress 2019 – State of the art session: Pulmonary vascular diseases Year: 2019 Beyond oestrogens: towards a broader evaluation of the hormone profile in pulmonary arterial hypertension Source: Eur Respir J, 51 (6) 1801058; 10.1183/13993003.01058-2018 Year: 2018 Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target Source: Eur Respir J 2011; 38: 1453-1460 Year: 2011 BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension Source: Eur Respir J 2016; 48: 1668-1681 Year: 2016 The emerging role of the contractile and vascular reserves in pulmonary arterial hypertension Source: Eur Respir J 2015; 45: 1758-1759 Year: 2015 The emerging role of the contractile and vascular reserves in pulmonary arterial hypertension Source: Eur Respir J 2015; 45: 1756-1758 Year: 2015 Targeting BMPR-II in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary arterial hypertension: future therapeutic approaches Year: 2016 MIF/CD74 contributes to the endothelial pro-inflammatory phenotype in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 Inflammatory mediators contribute to pulmonary arterial cell dysfunction in a pulmonary arterial hypertension patient with BMPR2 mutation Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013